Selected research
Industry Growth & Trends
Global Parkinson's Disease Treatments Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Parkinson's Disease Treatments market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Parkinson's Disease Treatments market include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Parkinson's Disease Treatments market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Parkinson's Disease Treatments market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Parkinson's Disease Treatments market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Parkinson's Disease Treatments.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Parkinson's Disease Treatments market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Parkinson's Disease Treatments Market by Company
GSK
Teva
Sun Pharma
Novartis
Merck
Abbvie
Wockhardt
UCB
Lundbeck
Impax
Boehringer Ingelheim
Bausch Health
Acadia
Parkinson's Disease Treatments Segment by Type
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Apomorphine
Dopamine Agonists
Glutamate Antagonist
Levodopa
Other Drugs
Parkinson's Disease Treatments Segment by Application
Hospitals
Healthcare Institutes
Others
Parkinson's Disease Treatments Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Parkinson's Disease Treatments companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- COMT Inhibitors Anticholinergics
- MAO-B Inhibitors
- Apomorphine
- Dopamine Agonists
- Glutamate Antagonist
- Levodopa
- Other Drugs
Applications
- Hospitals
- Healthcare Institutes
- Others
Companies covered
- GSK
- Teva
- Sun Pharma
- Novartis
- Merck
- Abbvie
- Wockhardt
- UCB
- Lundbeck
- Impax
- Boehringer Ingelheim
- Bausch Health
- Acadia
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Parkinson's Disease Treatments Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Parkinson's Disease Treatments Market Size by Region (2021-2032)
- 1.4.1 Global Parkinson's Disease Treatments Market Size by Region (2021-2026)
- 1.4.2 Global Parkinson's Disease Treatments Market Size by Region (2027-2032)
- 1.5 Key Regions Parkinson's Disease Treatments Market Size (2021-2032)
- 1.5.1 North America Parkinson's Disease Treatments Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Parkinson's Disease Treatments Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Parkinson's Disease Treatments Market Size Growth Rate (2021-2032)
- 1.5.4 South America Parkinson's Disease Treatments Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Parkinson's Disease Treatments Market Size Growth Rate (2021-2032)
2 Parkinson's Disease Treatments Market by Type
- 2.1 Type Introduction
- 2.1.1 COMT Inhibitors Anticholinergics
- 2.1.2 MAO-B Inhibitors
- 2.1.3 Apomorphine
- 2.1.4 Dopamine Agonists
- 2.1.5 Glutamate Antagonist
- 2.1.6 Levodopa
- 2.1.7 Other Drugs
- 2.2 Global Parkinson's Disease Treatments Market Size by Type
- 2.2.1 Global Parkinson's Disease Treatments Market Size Overview by Type (2021-2032)
- 2.2.2 Global Parkinson's Disease Treatments Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Parkinson's Disease Treatments Market Size Forecasted by Type (2027-2032)
- 2.3 Global Parkinson's Disease Treatments Market Size by Regions
- 2.3.1 North America Parkinson's Disease Treatments Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Parkinson's Disease Treatments Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Parkinson's Disease Treatments Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Parkinson's Disease Treatments Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Parkinson's Disease Treatments Market Size Breakdown by Type (2021-2026)
3 Parkinson's Disease Treatments Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Healthcare Institutes
- 3.1.3 Others
- 3.2 Global Parkinson's Disease Treatments Market Size by Application
- 3.2.1 Global Parkinson's Disease Treatments Market Size Overview by Application (2021-2032)
- 3.2.2 Global Parkinson's Disease Treatments Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Parkinson's Disease Treatments Market Size Forecasted by Application (2027-2032)
- 3.3 Global Parkinson's Disease Treatments Market Size by Regions
- 3.3.1 North America Parkinson's Disease Treatments Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Parkinson's Disease Treatments Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Parkinson's Disease Treatments Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Parkinson's Disease Treatments Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Parkinson's Disease Treatments Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Parkinson's Disease Treatments Industry Trends
- 4.2 Parkinson's Disease Treatments Industry Drivers
- 4.3 Parkinson's Disease Treatments Industry Opportunities and Challenges
- 4.4 Parkinson's Disease Treatments Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Parkinson's Disease Treatments Revenue (2021-2026)
- 5.2 Global Parkinson's Disease Treatments Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Parkinson's Disease Treatments Key Company Headquarters & Area Served
- 5.4 Global Parkinson's Disease Treatments Company, Product Type & Application
- 5.5 Global Parkinson's Disease Treatments Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Parkinson's Disease Treatments Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Parkinson's Disease Treatments Players Market Share by Revenue in 2025
- 5.6.3 2025 Parkinson's Disease Treatments Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 GSK
- 6.1.1 GSK Company Information
- 6.1.2 GSK Business Overview
- 6.1.3 GSK Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 GSK Parkinson's Disease Treatments Product Portfolio
- 6.1.5 GSK Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Parkinson's Disease Treatments Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sun Pharma
- 6.3.1 Sun Pharma Company Information
- 6.3.2 Sun Pharma Business Overview
- 6.3.3 Sun Pharma Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sun Pharma Parkinson's Disease Treatments Product Portfolio
- 6.3.5 Sun Pharma Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novartis Parkinson's Disease Treatments Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Merck
- 6.5.1 Merck Company Information
- 6.5.2 Merck Business Overview
- 6.5.3 Merck Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Merck Parkinson's Disease Treatments Product Portfolio
- 6.5.5 Merck Recent Developments
- 6.6 Abbvie
- 6.6.1 Abbvie Company Information
- 6.6.2 Abbvie Business Overview
- 6.6.3 Abbvie Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Abbvie Parkinson's Disease Treatments Product Portfolio
- 6.6.5 Abbvie Recent Developments
- 6.7 Wockhardt
- 6.7.1 Wockhardt Company Information
- 6.7.2 Wockhardt Business Overview
- 6.7.3 Wockhardt Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Wockhardt Parkinson's Disease Treatments Product Portfolio
- 6.7.5 Wockhardt Recent Developments
- 6.8 UCB
- 6.8.1 UCB Company Information
- 6.8.2 UCB Business Overview
- 6.8.3 UCB Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 UCB Parkinson's Disease Treatments Product Portfolio
- 6.8.5 UCB Recent Developments
- 6.9 Lundbeck
- 6.9.1 Lundbeck Company Information
- 6.9.2 Lundbeck Business Overview
- 6.9.3 Lundbeck Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Lundbeck Parkinson's Disease Treatments Product Portfolio
- 6.9.5 Lundbeck Recent Developments
- 6.10 Impax
- 6.10.1 Impax Company Information
- 6.10.2 Impax Business Overview
- 6.10.3 Impax Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Impax Parkinson's Disease Treatments Product Portfolio
- 6.10.5 Impax Recent Developments
- 6.11 Boehringer Ingelheim
- 6.11.1 Boehringer Ingelheim Company Information
- 6.11.2 Boehringer Ingelheim Business Overview
- 6.11.3 Boehringer Ingelheim Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio
- 6.11.5 Boehringer Ingelheim Recent Developments
- 6.12 Bausch Health
- 6.12.1 Bausch Health Company Information
- 6.12.2 Bausch Health Business Overview
- 6.12.3 Bausch Health Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Bausch Health Parkinson's Disease Treatments Product Portfolio
- 6.12.5 Bausch Health Recent Developments
- 6.13 Acadia
- 6.13.1 Acadia Company Information
- 6.13.2 Acadia Business Overview
- 6.13.3 Acadia Parkinson's Disease Treatments Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Acadia Parkinson's Disease Treatments Product Portfolio
- 6.13.5 Acadia Recent Developments
7 North America
- 7.1 North America Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 7.3 North America Parkinson's Disease Treatments Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 8.3 Europe Parkinson's Disease Treatments Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Parkinson's Disease Treatments Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 10.3 South America Parkinson's Disease Treatments Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Parkinson's Disease Treatments Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Parkinson's Disease Treatments Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst